Reagan Jarvis
Chief Executive Officer & Co-Founder Anocca
Reagan Jarvis is the Co-Founder and CEO of Anocca, a T-cell immunotherapy company based out of Sweden, commencing first-in-human clinical trials in 2025 with gene-edited TCR-T cell therapy products in oncology. A New Zealander, Jarvis obtained his PhD in Biochemistry at University of Otago and performed postdoctoral research at the University of Otago and thereafter the German Cancer Research Center (DKFZ) in Heidelberg. He founded Anocca with Mikael Blomqvist in 2014. Anocca currently has a pipeline of over 40 products. It has 130+ staff, with 40+ nationalities and operates its own cGMP cell therapy manufacturing site in Södertälje, south of Stockholm.
Seminars
Tuesday 19th May 2026
C-Level Fireside Chat: Reflecting on Lessons from TCR Therapies to Drive Next-Generation Strategies
9:00 am
- Identifying pivotal learnings that can sharpen development strategies and accelerate stronger clinical outcomes
- Framing actionable insights that translate early proof-of-concept gains into durable, real-world clinical impact
- Exploring critical knowledge gaps and defining high-value priorities that can shape the next-generation of TCR innovations
Tuesday 19th May 2026
Balancing Personalization & Scalability in Next-Generation TCR Therapies to Expand Patient Access
5:00 pm
- Examining how personalization can sharpen therapeutic precision while introducing cost and complexity trade-offs critical for strategic planning
- Comparing personalized and shared TCR strategies to identify the optimal balance of precision, accessibility, and real-world patient reach
- Designing regulatory and manufacturing pathways that enable scalable, compliant use of personalized TCR therapies
